Results 141 to 150 of about 101,656 (254)

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer

open access: yesCancer Science, EarlyView.
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto   +9 more
wiley   +1 more source

Indole‐3‐Propionic Acid Drives Dendritic H3K27 Acetylation to Enhance CD8+ T Cell Immunity in Hepatocellular Carcinoma

open access: yesCancer Science, EarlyView.
The gut microbiota metabolite indole ‐ 3 ‐ propionic acid(IPA) enhanced the inhibitory effect of SCB on tumor growth in HCC mice. IPA upregulated IL‐12A expression through facilitating acetylation of H3K27 in DCs. IPA elevated IL‐12A expression in DCs to promote CD8+ T cell anti‐tumor immunity and ultimately enhances the efficacy of SCB therapy against
Rui Zhao   +7 more
wiley   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

open access: yesCancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode   +21 more
wiley   +1 more source

Granulocyte Colony-Stimulating-Factor-Producing Bladder Carcinoma: A Case Report and Literature Review. [PDF]

open access: yesCureus
Yamashita K   +7 more
europepmc   +1 more source

Temporal dynamics of immune effector cell‐associated haematotoxicity: Linking early and late cytopenias after chimeric antigen receptor T cells

open access: yes
British Journal of Haematology, EarlyView.
Malvina Bichon   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy